Zydus Lifesciences climbs on planning to launch Semaglutide injection in India
Zydus Lifesciences is currently trading at Rs. 941.50, up by 22.10 points or 2.40% from its previous closing of Rs. 919.40 on the BSE.
The scrip opened at Rs. 937.90 and has touched a high and low of Rs. 947.70 and Rs. 922.20 respectively. So far 21972 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1059.00 on 19-Sep-2025 and a 52 week low of Rs. 797.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 947.70 and Rs. 898.55 respectively. The current market cap of the company is Rs. 94354.56 crore.
The promoters holding in the company stood at 75.00% while Institutions and Non-Institutions held 18.15% and 6.85% respectively.
Zydus Lifesciences has planned to launch Semaglutide Injection under the brand names -- Semaglyn, Mashema and Alterme, upon Semaglutide patent expiry in India. The Drug Controller General of India (DCGI) had earlier provided its approval for manufacturing and marketing Semaglutide injection for the treatment of Type 2 Diabetes Mellitus and Obesity.
A critical differentiator of Zydus’ Semaglutide offering will be its novel, indigenously developed drug-delivery system. Unlike existing treatments that require patients to purchase multiple single-dose pens as they titrate their dosage, Zydus plans to introduce an innovative, adjustable single-pen device. This technology allows patients to seamlessly select and administer varying dose strengths from a single unit, significantly enhancing patient adherence, maximizing convenience and drastically reducing the overall cost of therapy.
Zydus has exclusive rights to this novel device, which will be able to deliver all strengths approved for Type 2 Diabetes Mellitus and Obesity. The pen will also be reusable bringing in greater affordability for the patients.
.jpg)
